Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Buscar Study Connect
Ícono de BMS, studio Reclutando

Recruiting

ID del estudio CA240-0007  |   NCT05245500

Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Resumen

  • Phase 1/Phase 2
  • Ícono de género masculino y femenino
  • 18+
  • 21
  • Ícono de BMS, studio Reclutando
    Recruiting

Descripción general

This is a Phase 1/2, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Imprimir Imprimir
Email Correo electrónico

Centro de reclutamiento más cercano

Criterios clave de elegibilidad

Criterios de inclusión

Criterios de inclusión Icon
:
  • Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue or ctDNA
    1. Unresectable or metastatic disease.
      1. Patients must have received standard therapies appropriate for their tumor type and stage with disease progression on or after the most recent treatment. 1. Phase 1 dose escalation, RECIST 1.1 measurable or evaluable disease 2. Phase 1b and Phase 2 cohorts, RECIST 1.1 measurable disease.
        1. Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.
          1. Age ≥ 18 years.
            1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
              1. Adequate organ function

                Criterios de exclusión

                Criterios de exclusión Icon
                :
                • Prior treatment with a PRMT5 or MAT2A inhibitor therapy.
                  1. Active brain metastases or carcinomatous meningitis.
                    1. History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
                      1. Major surgery within 4 weeks of first dose of study treatment.
                        1. History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications
                          1. Cardiac abnormalities
                            Información Adicional *

                            Opciones de tratamiento

                            Brazos del estudio

                            INTERVENCIÓN ASIGNADA

                            Brazos del estudio

                            Experimental: Phase 1/1B

                            INTERVENCIÓN ASIGNADA
                            • Drug: MRTX1719

                            Brazos del estudio

                            Experimental: Phase 1b Sub-Study

                            INTERVENCIÓN ASIGNADA
                            • Drug: MRTX1719

                            Brazos del estudio

                            Experimental: Phase 2

                            INTERVENCIÓN ASIGNADA
                            • Drug: MRTX1719
                            Dé el primer paso para ver si es compatible con un estudio clínico - Verifique su elegibilidad
                            Verifique su elegibilidad
                            Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
                            Compatibilizar con un estudio
                            Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
                            Seleccione una ubicación del centro del estudio
                            Seleccione una ubicación del centro del estudio que sea conveniente para usted
                            Registrarse
                            Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

                            Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
                            Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
                            Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica

                            ¿Tiene alguna pregunta? El soporte en vivo está disponible 24/7 - Llame 855-907-3286 o Envíenos un correo electrónico

                            ¿Tiene alguna pregunta? El soporte en vivo está disponible 24/7 -
                            Llame 855-907-3286 o Envíenos un correo electrónico